DrugsNews.net

Drugs Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

FDA has approved Pradaxa for children with venous thromboembolism


The U.S. Food and Drug Administration ( FDA ) has approved Pradaxa ( Dabigatran etexilate ) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism directly after they have been treated with a blood thinner given by injection for at least five days.

In addition, Pradaxa was approved in capsule form to treat blood clots in patients eight years and older with venous thromboembolism directly after they have been treated with a blood thinner given by injection for at least five days, and to prevent recurrent clots in patients eight years and older who completed treatment for their first venous thromboembolism.

Pradaxa is the first FDA-approved blood thinning medication that children can take by mouth; the only other approved blood thinning medication for children is given by injection.
Pradaxa was originally approved in 2010 to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.

Blood clots can be a serious problem in children as well as adults. Children are most at risk for blood clots if they have cancer, congenital heart disease, a central venous catheter, or are admitted to an intensive care unit.
Venous thromboembolism can lead to complications, including swelling and discomfort near the clot, chest pain, lung damage, and even death.

The safety and efficacy of Pradaxa for treating blood clots in patients younger than 18 was evaluated in one study of 267 pediatric patients.
In this open-label study, patients were randomly assigned to receive either Pradaxa or standard of care.
The study has compared the two groups for the number of patients who met the composite endpoint ( a combination of multiple clinical endpoints ), which meant that they had not died from a blood clot, their blood clots had completely resolved, and they had no additional blood clots.
Results have shown that 81 ( 45.8% ) of the 177 people taking Pradaxa met the composite endpoint compared to 38 ( 42.2% ) of the 90 patients who received standard of care.

The safety of Pradaxa to prevent recurrent blood clots in the same pediatric population was evaluated in an open-label, single-arm study in 214 patients with a history of blood clots.
The primary endpoints of the study were recurrence of blood clots, major and minor bleeding events, and death ( both overall and related to blood clots ).
The safety of Pradaxa with long-term use was similar to the previously discussed study. Recurrence of blood clots occurred in three patients ( 1.4% ), which was comparable to prior standard-of-care treatments.

The most common side effects of Pradaxa include digestive system symptoms and bleeding. Pradaxa can cause serious and fatal bleeding.

Pradaxa is not recommended for patients with bioprosthetic heart valves or triple-positive antiphospholipid syndrome.

Pradaxa has a boxed warning cautioning that early treatment discontinuation may increase the risk of blood clots and that blood accumulation within parts of the spinal cord ( spinal or epidural hematomas ) in patients undergoing spinal procedures may cause serious side effects. ( Xagena )

Source: FDA, 2021

XagenaMedicine_2021



Indietro